Keryx Biopharmaceuticals (KERX)
Keryx Biopharmaceuticals SG&A Expense: 1.776M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KERX SG&A Expense Rankings
| Overall | 92nd percentile | 313 of 4189 |
| Sector | 87th percentile | 63 of 485 in Healthcare |
| Industry | 84th percentile | 4 of 26 in Drug Manufacturers - Major |
KERX SG&A Expense Range, Past 5 Years
| Minimum | 0.898M | Mar 2010 |
| Maximum | 3.946M | Sep 2008 |
| Average | 2.362M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these KERX related companies
KERX News
$KERX and i was thinking 2, two weeks ago! I was wrong. counting on u being right
about 9 hours ago by Bleedblue
about 9 hours ago by Bleedblue
$AMRN $kerx $arna $gale bullish on all with FDA Asco such events on the way
about 9 hours ago by newkidontheblock
about 9 hours ago by newkidontheblock
Ceo has over 400k shares conditional upon positive zerenex and fda approval. Thats a big carrot! $kerx is best when volume dry and lonely...
about 9 hours ago by HighRiskBuyer
about 9 hours ago by HighRiskBuyer
RT @gregthor $KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 12 hours ago by JasonMilano8
about 12 hours ago by JasonMilano8
@adamfeuerstein @Gekkowire what do these free shares mean? $kerx
about 13 hours ago by GucciMoccasins
about 13 hours ago by GucciMoccasins
$KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 15 hours ago by gregthor
about 15 hours ago by gregthor
$KERX Stock better run soon ugh money tied up is less money to be had
about 17 hours ago by newkidontheblock
about 17 hours ago by newkidontheblock
$AMRN will buy at $10.55, $KERX will buy at $1.66, $SPPI will buy at $10.75
about 17 hours ago by JasonMilano8
about 17 hours ago by JasonMilano8
RT @traderstewie $KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 18 hours ago by SomeGuy900
about 18 hours ago by SomeGuy900
$KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 19 hours ago by SomeGuy900
about 19 hours ago by SomeGuy900
$KERX Reading rumors about secondary offering. Do you think it could happen? This stock is like playing craps in Vegas.
about 20 hours ago by Scott_biotech
about 20 hours ago by Scott_biotech
$kerx nevermind, i see it now. Looking for 2 today and more the next couple of days.
about a day ago by HighRiskBuyer
about a day ago by HighRiskBuyer
M&A Activity and Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Recent Boom
May 21, 8:20AM Marketwire
May 21, 8:20AM Marketwire
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT
May 10, 10:54AM Benzinga
May 10, 10:54AM Benzinga
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
May 10, 8:30AM PR Newswire
May 10, 8:30AM PR Newswire
Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America
May 07, 7:40AM Street Insider
May 07, 7:40AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 1.70 | -0.05 | -2.86% | 120.73M |
| KALU | 50.67 | +1.21 | +2.45% | 975.40M |
| K | 50.48 | +0.21 | +0.42% | 18.03B |
| JYF | 32.24 | -0.09 | -0.28% | |
| JXSB | 17.76 | +0.42 | +2.40% | 34.09M |
| JXI | 40.61 | -0.21 | -0.51% | |
| JWN | 51.08 | +0.34 | +0.67% | 10.62B |
| JVA | 7.89 | +0.30 | +3.95% | 50.26M |
| JTP | 8.26 | -0.01 | -0.12% | |
| JST | 7.25 | -0.35 | -4.61% | 118.90M |
